Vandetanib

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer

(2010) Fiona H. Blackhall et al.   Journal of Thoracic Oncology

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer

(2009) József Horti et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

(2009) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2008) John V. Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY